How Effective is VELCADE® (bortezomib)?
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial - The Lancet Oncology
Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-Analysis | PLOS ONE
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study - Clinical Lymphoma, Myeloma and Leukemia
How to Treat High-Risk Myeloma at Diagnosis and Relapse | American Society of Clinical Oncology Educational Book
Results of prospective clinical trials on the use of bortezomib as a... | Download Table
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet
Bortezomib - Wikipedia
Levine Cancer Institute Myeloma Trials
Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial | BMJ Open
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy | Leukemia
Newly Diagnosed Myeloma in 2020 | American Society of Clinical Oncology Educational Book
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma | NEJM
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies | Nature Reviews Clinical Oncology
Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents (Open) - JADPRO
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial - The Lancet
BELLINI Trial at ASCO 2020 | Int'l Myeloma Foundation
Bortezomib (Velcade™) in the Treatment of Multiple Myeloma | Semantic Scholar
Clinical trials of bendamustine with or without bortezomib | Download Table
Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Study Identifies Safety Concern about Bortezomib as Post-Transplant GVHD Prophylaxis in High-Risk Multiple Myeloma – Consult QD
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial - ScienceDirect
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma - Clinical Lymphoma, Myeloma and Leukemia
